Have Insiders Been Selling CONMED Corporation (NASDAQ:CNMD) Shares This Year?

We’ve lost count of how many times insiders have accumulated shares in a company that goes on to improve markedly. On the other hand, we’d be remiss not to mention that insider sales have been known to precede tough periods for a business. So before you buy or sell CONMED Corporation (NASDAQ:CNMD), you may well want to know whether insiders have been buying or selling.

What Is Insider Buying?

It’s quite normal to see company insiders, such as board members, trading in company stock, from time to time. However, most countries require that the company discloses such transactions to the market.

We would never suggest that investors should base their decisions solely on what the directors of a company have been doing. But equally, we would consider it foolish to ignore insider transactions altogether. For example, a Columbia University study found that ‘insiders are more likely to engage in open market purchases of their own company’s stock when the firm is about to reveal new agreements with customers and suppliers’.

See our latest analysis for CONMED

The Last 12 Months Of Insider Transactions At CONMED

In the last twelve months, the biggest single sale by an insider was when the insider, Terence Berge, sold US$789k worth of shares at a price of US$95.02 per share. That means that an insider was selling shares at slightly below the current price (US$114). As a general rule we consider it to be discouraging when insiders are selling below the current price, because it suggests they were happy with a lower valuation. Please do note, however, that sellers may have a variety of reasons for selling, so we don’t know for sure what they think of the stock price. We note that the biggest single sale was only 29% of Terence Berge’s holding.

We note that in the last year insiders divested 32184 shares for a total of US$2.8m. In the last year CONMED insiders didn’t buy any company stock. You can see a visual depiction of insider transactions (by individuals) over the last 12 months, below. If you click on the chart, you can see all the individual transactions, including the share price, individual, and the date!

I will like CONMED better if I see some big insider buys. While we wait, check out this free list of growing companies with considerable, recent, insider buying.

NasdaqGS:CNMD Recent Insider Trading, December 8th 2019
NasdaqGS:CNMD Recent Insider Trading, December 8th 2019

Insider Ownership

I like to look at how many shares insiders own in a company, to help inform my view of how aligned they are with insiders. We usually like to see fairly high levels of insider ownership. CONMED insiders own about US$80m worth of shares. That equates to 2.5% of the company. While this is a strong but not outstanding level of insider ownership, it’s enough to indicate some alignment between management and smaller shareholders.

What Might The Insider Transactions At CONMED Tell Us?

It doesn’t really mean much that no insider has traded CONMED shares in the last quarter. We don’t take much encouragement from the transactions by CONMED insiders. But we do like the fact that insiders own a fair chunk of the company. Therefore, you should should definitely take a look at this FREE report showing analyst forecasts for CONMED.

Of course, you might find a fantastic investment by looking elsewhere. So take a peek at this free list of interesting companies.

For the purposes of this article, insiders are those individuals who report their transactions to the relevant regulatory body. We currently account for open market transactions and private dispositions, but not derivative transactions.

If you spot an error that warrants correction, please contact the editor at editorial-team@simplywallst.com. This article by Simply Wall St is general in nature. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. Simply Wall St has no position in the stocks mentioned.

We aim to bring you long-term focused research analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Thank you for reading.